ATE419345T1 - Konjugate von löslichen peptidischen verbindungen mit membranbindenden wirkstoffen - Google Patents

Konjugate von löslichen peptidischen verbindungen mit membranbindenden wirkstoffen

Info

Publication number
ATE419345T1
ATE419345T1 AT97933665T AT97933665T ATE419345T1 AT E419345 T1 ATE419345 T1 AT E419345T1 AT 97933665 T AT97933665 T AT 97933665T AT 97933665 T AT97933665 T AT 97933665T AT E419345 T1 ATE419345 T1 AT E419345T1
Authority
AT
Austria
Prior art keywords
actives
conjugates
membrane
binding
peptidic compounds
Prior art date
Application number
AT97933665T
Other languages
English (en)
Inventor
Richard Anthony Godwin Smith
Ian Dodd
Danuta Ewa Irena Mossakowska
Original Assignee
Adprotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adprotech Ltd filed Critical Adprotech Ltd
Application granted granted Critical
Publication of ATE419345T1 publication Critical patent/ATE419345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97933665T 1996-07-15 1997-07-08 Konjugate von löslichen peptidischen verbindungen mit membranbindenden wirkstoffen ATE419345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9614871.3A GB9614871D0 (en) 1996-07-15 1996-07-15 Compounds

Publications (1)

Publication Number Publication Date
ATE419345T1 true ATE419345T1 (de) 2009-01-15

Family

ID=10796956

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933665T ATE419345T1 (de) 1996-07-15 1997-07-08 Konjugate von löslichen peptidischen verbindungen mit membranbindenden wirkstoffen

Country Status (17)

Country Link
US (3) US6713606B1 (de)
EP (1) EP0912730B1 (de)
JP (1) JP4177457B2 (de)
AR (1) AR007737A1 (de)
AT (1) ATE419345T1 (de)
AU (1) AU732725B2 (de)
CA (1) CA2260288A1 (de)
CO (1) CO4750673A1 (de)
DE (1) DE69739186D1 (de)
DK (1) DK0912730T3 (de)
ES (1) ES2321245T3 (de)
GB (1) GB9614871D0 (de)
IL (3) IL128034A0 (de)
NZ (1) NZ333722A (de)
TW (1) TW538048B (de)
WO (1) WO1998002454A2 (de)
ZA (1) ZA976216B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614871D0 (en) * 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9704519D0 (en) 1997-03-05 1997-04-23 Smithkline Beecham Plc Compounds
IL136230A0 (en) 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
EP0953576B1 (de) 1998-04-30 2005-11-02 Curis, Inc. Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
GB0016811D0 (en) * 2000-07-07 2000-08-30 Adprotech Ltd Lipid rafts
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
GB0117193D0 (en) * 2001-07-13 2001-09-05 Adprotech Ltd Protein modification reagents
GB0123262D0 (en) * 2001-09-27 2001-11-21 Adprotech Ltd Polymeric compounds
GB0220936D0 (en) 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents
FR2854897B1 (fr) * 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.
US7858108B2 (en) * 2003-10-21 2010-12-28 Richard Nagler Elutable surface coating
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
WO2005115430A1 (en) 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
JP2009508937A (ja) * 2005-09-22 2009-03-05 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｔ細胞免疫を調節するためのジアステレオマーペプチド
WO2007103548A2 (en) 2006-03-09 2007-09-13 Inflazyme Pharmaceuticals Ltd. Novel antibiotic compositions
WO2008048675A2 (en) 2006-10-20 2008-04-24 Celldex Therapeutics, Inc. Treatment for age-related macular degeneration and other diseases of the eye
EP2839839B1 (de) 2007-02-28 2018-01-17 Yeda Research And Development Company Limited Nuklear-Targeting-Sequenzen
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
CN102325544A (zh) * 2009-02-20 2012-01-18 益普生制药股份有限公司 具有34位脯氨酸替换的神经肽y的类似物
US9428564B2 (en) 2009-04-16 2016-08-30 Universitatsklinikum Heidelberg Muscle function enhancing peptide
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
WO2011050334A1 (en) * 2009-10-22 2011-04-28 Yong Zhu Compositions and methods for re-programming cells without genetic modification for treatment of obesity and related diseases
CA2811291C (en) 2010-09-15 2018-05-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type i (scr1)
US9649356B2 (en) 2010-10-27 2017-05-16 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type I (sCR1)
US9988611B2 (en) 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
GB201402267D0 (en) 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN110240656A (zh) * 2019-04-24 2019-09-17 中山大学附属第三医院 一种融合蛋白及其制备方法与应用
CN110551177A (zh) * 2019-08-29 2019-12-10 安徽瑞达健康产业有限公司 多肽、多肽衍生物、多肽-抗体复合物及制备、应用
GB201913804D0 (en) 2019-09-25 2019-11-06 Prostate Cancer Res Centre Fusion polypeptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109653A3 (de) 1982-11-17 1986-01-29 Otsuka Pharmaceutical Co., Ltd. Verfahren zur Herstellung eines Urokinasekomplexes
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
GB8334498D0 (en) 1983-12-24 1984-02-01 Beecham Group Plc Compounds
GB8400653D0 (en) 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
EP0207589A1 (de) 1985-04-03 1987-01-07 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
JP2573007B2 (ja) * 1987-12-28 1997-01-16 株式会社成和化成 修飾された動物毛粉末
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5326700A (en) 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
DE69328098T2 (de) * 1992-06-24 2000-08-24 Adprotech Plc Lösliche derivate des complement type-rezeptors (cr1)
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ATE215094T1 (de) * 1993-05-17 2002-04-15 Avant Immunotherapeutics Inc Komplement verwandte proteine und kohlenhydrate enthaltende zusammensetzungen und methoden zur herstellung und verwendung dieser zusammensetzungen
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
EP0750458B1 (de) * 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Fusionsgene für den inhibitor des terminalen komplements und proteine
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US5776689A (en) 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
WO2000020867A1 (en) 1998-10-01 2000-04-13 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
GB0220936D0 (en) * 2002-09-05 2002-10-23 Adprotech Ltd Modified therapeutic agents

Also Published As

Publication number Publication date
AU3693997A (en) 1998-02-09
IL128034A (en) 2007-03-08
CA2260288A1 (en) 1998-01-22
IL128034A0 (en) 1999-11-30
US20100286367A1 (en) 2010-11-11
DK0912730T3 (da) 2009-04-27
AR007737A1 (es) 1999-11-10
CO4750673A1 (es) 1999-03-31
ES2321245T3 (es) 2009-06-03
IL166051A0 (en) 2006-01-15
NZ333722A (en) 2000-09-29
GB9614871D0 (en) 1996-09-04
TW538048B (en) 2003-06-21
EP0912730A2 (de) 1999-05-06
WO1998002454A3 (en) 1998-04-02
AU732725B2 (en) 2001-04-26
ZA976216B (en) 1999-04-14
WO1998002454A2 (en) 1998-01-22
US6713606B1 (en) 2004-03-30
EP0912730B1 (de) 2008-12-31
JP2000515370A (ja) 2000-11-21
US20040266684A1 (en) 2004-12-30
JP4177457B2 (ja) 2008-11-05
US7655617B2 (en) 2010-02-02
DE69739186D1 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE419345T1 (de) Konjugate von löslichen peptidischen verbindungen mit membranbindenden wirkstoffen
ATE200027T1 (de) Tetrahydrolipstatin enthaltende präparate
FI944969A0 (fi) Indolijohdannaisia
FR2694651B1 (fr) Ensemble combine affichette-catalogue.
DE69312986D1 (de) Stalldungstreuer
BR9612447A (pt) Fertilizante
DE550018T1 (de) Streugerät.
DE68900672D1 (de) Strassenkehrmaschine.
DE29601934U1 (de) Gülleverteiler
NO985084D0 (no) Vial
DE69801242T2 (de) Düngerstreuer
DE59700916D1 (de) Düngevorrichtung
DE29711409U1 (de) Pflanzgefäß
KR970053060U (ko) 더블 비료살포기
DE29609874U1 (de) Gülleverteiler
FI970078A0 (fi) Kylvökone
FR2689152B1 (fr) Musoir autoroutier.
KR980000012U (ko) 비료 주입기
DE29717968U1 (de) Zerlegbares Pflanzgefäß
DE29612113U1 (de) Gülleverteiler
DE29609829U1 (de) Flüssige Bodenaktivierung
ES1038803Y (es) Jardinera.
KR970056631U (ko) 우의가 구비된 가방
DE29714115U1 (de) Gülleverteiler
KR970060215U (ko) 파종기

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties